By: Corinna Dan, RN, MPH, Viral Hepatitis Policy Advisor, Office of HIV/AIDS and Infectious Disease Policy, U.S. Department of Health and Human Services
New hepatitis B resource supports providers in hepatitis B testing, vaccination, and linkage to care, highlights key actions to increase hepatitis B services.
By: Corinna Dan, RN, MPH, Viral Hepatitis Policy Advisor, Office of HIV/AIDS and Infectious Disease Policy, U.S. Department of Health and Human Services
Free Continuing Medical and Nursing Education credits are now available for the HIV/HCV co-infection curriculum from the HRSA Ryan White HIV/AIDS Program.
By: Corinna Dan, RN, MPH, Viral Hepatitis Policy Advisor, Office of HIV/AIDS and Infectious Disease Policy, U.S. Department of Health and Human Services
New HHS/AHRQ analysis examines trends in the number and rate of hepatitis C-related inpatient hospital stays, underscoring increasing healthcare burden.
New research from the CDC suggests that the recent steep increase in cases of acute hepatitis C virus infection is associated with increases in opioid injection.
By: Corinna Dan, RN, MPH, Viral Hepatitis Policy Advisor, Office of HIV/AIDS and Infectious Disease Policy, U.S. Department of Health and Human Services
Responding to hepatitis A outbreaks requires partnerships between health departments, health centers, homeless service providers, & substance abuse services.
By: Corinna Dan, RN, MPH, Viral Hepatitis Policy Advisor, Office of HIV/AIDS and Infectious Disease Policy, U.S. Department of Health and Human Services and Richard Wolitski, Ph.D., Director, Office of HIV/AIDS and Infectious Disease Policy, U.S. Department of Health and Human Services
Two webinars featured individuals and experts from the 11 priority populations in the National Viral Hepatitis Action Plan sharing their perspectives.
By: Corinna Dan, RN, MPH, Viral Hepatitis Policy Advisor, Office of HIV/AIDS and Infectious Disease Policy, U.S. Department of Health and Human Services
The guidance provides updated FDA recommendations regarding the overall development program and clinical trial designs to support improved hepatitis C treatments.
By: Robert Gish, MD, Medical Director, Hepatitis B Foundation and Grace Wang, MD, MPH, Family Physician, International Community Health Services
Offers a description of HBV reactivation that can occur alongside DAA treatment for HCV; discusses the new FDA black box warning for individuals starting DAA treatment for HCV; provide action steps for both patients and providers, in order to help prevent HBV reactivation and the negative health outcomes associated with it.
By: Corinna Dan, RN, MPH, Viral Hepatitis Policy Advisor, Office of HIV/AIDS and Infectious Disease Policy, U.S. Department of Health and Human Services
With increased Congressional funding, the Department of Veterans Affairs is planning to treat all veterans with chronic hepatitis C infection enrolled in VA.
